EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real‐World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry

Ludmila Muronova iD, Ondrej Soucek, David Zihala, Tereza Sevcikova, Tereza Popkova, Hana Plonkova, Ondrej Venglar, Ludek Pour, Martin Stork iD, Lucie Rihova, Renata Bezdekova, Jiri Minarik iD und 11 weitere

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14316 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Ludmila Muronova und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm, Residual, Flow Cytometry. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union project LERCO, SALVAGE project, Czech Health Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Minimal residual disease (MRD) is one of the most important prognostic factors in multiple myeloma (MM) and a valid surrogate for progression‐free survival (PFS) and overall survival (OS). Recently, MRD negativity was approved as an early clinical endpoint for accelerated drug approval in MM. Nevertheless, there is limited evidence of MRD utility in real‐world setting. In this retrospective multicenter study, we report outcomes of 331 newly diagnosed MM patients with MRD evaluation at Day+100 after autologous stem cell transplantation using flow cytometry with a median limit of detection of 0.001%. MRD negativity was reached in 47% of patients and was associated with significantly prolonged median PFS (49.2 months vs. 18.4 months; hazard ratios (HR) = 0.37; p < 0.001) and OS (not reached vs. 74.9 months; HR = 0.50; p = 0.007). Achieving MRD negativity was associated with PFS improvements regardless of age, International Staging System (ISS) stage, lactate dedydrogenase (LDH) level, or cytogenetic risk. Importantly, MRD positive patients benefited from lenalidomide maintenance versus no maintenance (18‐months PFS: 81% vs. 46%; HR = 0.24; p = 0.002) while in MRD negative patients such benefit was not observed ( p = 0.747). The outcomes of our real‐world study recapitulate results from clinical trials including meta‐analyses and support the idea that MRD positive patients profit more from lenalidomide maintenance than MRD negative ones.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaNeoplasm, ResidualFlow CytometryHumansPrognosisFemaleMaleMiddle AgedAgedRetrospective StudiesAdultHematopoietic Stem Cell TransplantationTransplantation, AutologousTreatment OutcomeNeoplasm StagingLenalidomide

Stichwörter der Autor:innen

lenalidomide maintenanceminimal residual disease (MRD)multiparameter flow cytometrymultiple myelomaoverall survival (OS)progression‐free survival (PFS)real‐world

Substanzen

Lenalidomide

Autor:innen und Institutionen

  • Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Institute of Clinical Immunology and Allergology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic.
  • Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.

ORCID-Profile: Ludmila Muronova, Martin Stork, Jiri Minarik, Roman Hajek

Förderung

  • European Union project LERCO
  • SALVAGE project
  • Czech Health Research Council
  • Institutional support
  • Ministry of Health of the Czech Republic
  • Ministry of Education, Youth and Sports of the Czech Republic through the e-INFRA CZ
  • Agentura Pro Zdravotnický Výzkum České Republiky
  • Ministerstvo Zdravotnictví Ceské Republiky

Zitieren

APA

Muronova, L., Soucek, O., Zihala, D., Sevcikova, T., Popkova, T., Plonkova, H., Venglar, O., Pour, L., Stork, M., Rihova, L., Bezdekova, R., Minarik, J., Látal, V., Novak, M., Jungova, A., Dekojova, T., Straub, J., Spacek, M., Rezacova, V., …, & Jelinek, T. (2025). Real‐World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry. European Journal of Haematology. https://doi.org/10.1111/ejh.14316

Vancouver

Muronova L, Soucek O, Zihala D, Sevcikova T, Popkova T, Plonkova H, et al. Real‐World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry. European Journal of Haematology. 2025. doi:10.1111/ejh.14316

BibTeX
@article{Muronova2025,
  author = {Muronova, Ludmila and Soucek, Ondrej and Zihala, David and Sevcikova, Tereza and Popkova, Tereza and Plonkova, Hana and Venglar, Ondrej and Pour, Ludek and Stork, Martin and Rihova, Lucie and Bezdekova, Renata and Minarik, Jiri and Látal, Vojtech and Novak, Martin and Jungova, Alexandra and Dekojova, Tereza and Straub, Jan and Spacek, Martin and Rezacova, Vladimira and Maisnar, Vladimir and Radocha, Jakub and Hajek, Roman and Jelinek, Tomas},
  title = {Real‐World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14316}
}
Kostenlos starten →